Last reviewed · How we verify
Vedolizumab IV
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract. Used for Moderate to severe ulcerative colitis, Moderate to severe Crohn's disease.
At a glance
| Generic name | Vedolizumab IV |
|---|---|
| Also known as | MLN0002SC, Entyvio, MLN0002, ENTYVIO, KYNTELES |
| Sponsor | Takeda |
| Drug class | Integrin antagonist monoclonal antibody |
| Target | α4β7 integrin |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
By binding to α4β7 integrin expressed on memory T cells, vedolizumab prevents these cells from adhering to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. This selective gut-homing mechanism reduces intestinal inflammation while minimizing systemic immunosuppression, making it effective for inflammatory bowel diseases.
Approved indications
- Moderate to severe ulcerative colitis
- Moderate to severe Crohn's disease
Common side effects
- Nasopharyngitis
- Headache
- Arthralgia
- Pyrexia
- Fatigue
- Infections (serious)
Key clinical trials
- A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PHASE4)
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) (PHASE4)
- A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (PHASE3)
- Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) (PHASE2)
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
- Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vedolizumab IV CI brief — competitive landscape report
- Vedolizumab IV updates RSS · CI watch RSS
- Takeda portfolio CI